Palvella Therapeutics (PVLA) Invested Capital (2013 - 2026)
Palvella Therapeutics (PVLA) reported Invested Capital of $232.3 million for Q1 2026, up 303.64% year-over-year from $57.6 million in Q1 2025, and up 669.78% on a QoQ basis from $30.2 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Invested Capital data on file, last reported at $232.3 million in Q1 2026.
- Quarterly Invested Capital rose 303.64% year-over-year to $232.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $232.3 million (up 303.64% YoY) and the FY2025 annual result came in at $30.2 million, down 53.27% from the prior year.
- Invested Capital improved to $232.3 million in Q1 2026 per PVLA's latest filing, from $30.2 million in the prior quarter.
- Across five years, Invested Capital topped out at $232.3 million in Q1 2026 and bottomed at -$93.8 million in Q4 2022.
- The 5-year median for Invested Capital is $35.5 million (2023), against an average of $15.4 million.
- The widest annual swing landed in 2024, when Invested Capital slumped 597.3%; it then surged 303.64% in 2026.
- Tracing PVLA's Invested Capital over 5 years: stood at -$93.8 million in 2022, then advanced by 20.57% to -$74.5 million in 2023, then jumped by 186.71% to $64.6 million in 2024, then tumbled by 53.27% to $30.2 million in 2025, then surged by 669.78% to $232.3 million in 2026.
- Per Business Quant, the three latest PVLA Invested Capital figures stand at $232.3 million (Q1 2026), $30.2 million (Q4 2025), and $40.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 232.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 232.31 Mn |
| Dec 31, 2025 | 30.18 Mn |
| Sep 30, 2025 | 40.90 Mn |
| Jun 30, 2025 | 49.76 Mn |
| Mar 31, 2025 | 57.56 Mn |
| Dec 31, 2024 | 64.59 Mn |
| Sep 30, 2024 | -87.40 Mn |
| Jun 30, 2024 | -80.83 Mn |
| Mar 31, 2024 | -76.87 Mn |
| Dec 31, 2023 | -74.48 Mn |
| Sep 30, 2023 | 30.51 Mn |
| Jun 30, 2023 | 40.50 Mn |
| Mar 31, 2023 | 15.46 Mn |
| Dec 31, 2022 | -93.78 Mn |
| Jun 30, 2022 | 44.37 Mn |
| Mar 31, 2022 | 53.45 Mn |
| Dec 31, 2021 | 50.76 Mn |
| Sep 30, 2021 | 53.85 Mn |
| Jun 30, 2021 | 46.72 Mn |
| Mar 31, 2021 | 38.24 Mn |
| Dec 31, 2020 | 31.03 Mn |
| Sep 30, 2020 | 43.69 Mn |
| Jun 30, 2020 | 46.67 Mn |
| Mar 31, 2020 | 49.81 Mn |
| Dec 31, 2019 | 51.35 Mn |
| Sep 30, 2019 | 20.64 Mn |
| Jun 30, 2019 | 19.49 Mn |
| Mar 31, 2019 | 30.16 Mn |
| Dec 31, 2018 | 39.94 Mn |
| Sep 30, 2018 | 50.26 Mn |
| Jun 30, 2018 | 55.32 Mn |
| Mar 31, 2018 | 50.69 Mn |
| Dec 31, 2017 | 11.52 Mn |
| Sep 30, 2017 | 4.56 Mn |
| Jun 30, 2017 | 9.33 Mn |
| Mar 31, 2017 | 18.04 Mn |
| Dec 31, 2016 | 25.23 Mn |
| Sep 30, 2016 | 31.48 Mn |
| Jun 30, 2016 | 37.29 Mn |
| Mar 31, 2016 | 27.18 Mn |
| Dec 31, 2015 | 31.13 Mn |
| Sep 30, 2015 | 33.65 Mn |
| Jun 30, 2015 | 11.15 Mn |
| Mar 31, 2015 | 14.23 Mn |
| Dec 31, 2014 | 19.28 Mn |
| Sep 30, 2014 | 2,570.00 |
| Jun 30, 2014 | 10,488.00 |
| Mar 31, 2014 | -4,778.00 |
| Dec 31, 2013 | 791,497.00 |
| Jun 30, 2013 | 4,726.00 |